Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells

Gynecologic Oncology

Volumn 105, Issue 1, 2007, Pages 104-112

  Wahl, Heather ^a   Tan, Lijun ^a   Griffith, Kent ^b   Choi, Miheon ^a   Liu, J Rebecca ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Apo2L TRAIL; Apoptosis; Chemoresistance; Curcumin; Ovarian cancer

Indexed keywords

CASPASE 8; CASPASE 9; CISPLATIN; CURCUMIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME DEGRADATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CURCUMIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33947427176     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.10.050     Document Type: Article

References (34)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA: Cancer J. Clin. 55 1 (2005) 10-30
2. Vikhanskaya F., and Broggini M. Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients. Int. Rev. Cytol. 219 (2002) 157-198
3. Gadducci A., Cosio S., Muraca S., and Genazzani A.R. Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur. J. Gynaecol. Oncol. 23 5 (2002) 390-396
4. Coukos G., and Rubin S.C. Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet. Gynecol. 91 5 Pt. 1 (1998) 783-792
5. Hajra K.M., and Liu J.R. Apoptosome dysfunction in human cancer. Apoptosis 9 6 (2004) 691-704
6. Azuine M.A., and Bhide S.V. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr. Cancer 17 1 (1992) 77-83
7. Azuine M.A., and Bhide S.V. Protective single/combined treatment with betel leaf and turmeric against methyl (acetoxymethyl) nitrosamine-induced hamster oral carcinogenesis. Int. J. Cancer 51 3 (1992) 412-415
8. Azuine M.A., and Bhide S.V. Adjuvant chemoprevention of experimental cancer: catechin and dietary turmeric in forestomach and oral cancer models. J. Ethnopharmacol. 44 3 (1994) 211-217
9. Huang M.T., Lou Y.R., Ma W., Newmark H.L., Reuhl K.R., and Conney A.H. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 54 22 (1994) 5841-5847
10. Bush J.A., Cheung Jr. K.J., and Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp. Cell Res. 271 2 (2001) 305-314
11. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 2 (1999) 155-162
12. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 22 (1996) 12687-12690
13. Wiley S.R., Schooley K., Smolak P.J., Huang C.P., Nicholl J.K., Sutherland G.R., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 6 (1995) 673-682
14. Oltvai Z.N., Milliman C.L., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 4 (1993) 609-619
15. Merino R., Grillot D.A., Simonian P.L., Muthukkumar S., Fanslow W.C., Bondada S., et al. Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells. Dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction. J. Immunol. 155 8 (1995) 3830-3838
16. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139 2 (1991) 271-279
17. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82 (1990) 1107-1112
18. Lane D., Cartier A., L'Esperance S., Cote M., Rancourt C., and Piche A. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Gynecol. Oncol. 93 3 (2004) 594-604
19. Tomek S., Horak P., Pribill I., Haller G., Rossler M., Zielinski C.C., et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol. Oncol. 94 1 (2004) 107-114
20. Cuello M., Coats A.O., Darko I., Ettenberg S.A., Gardner G.J., Nau M.M., et al. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ. 11 5 (2004) 527-541
21. Deeb D., Xu Y.X., Jiang H., Gao X., Janakiraman N., Chapman R.A., et al. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol. Cancer Ther. 2 1 (2003) 95-103
22. Bharti A.C., Donato N., and Aggarwal B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 171 7 (2003) 3863-3871
23. Li L., Aggarwal B.B., Shishodia S., Abbruzzese J., and Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101 10 (2004) 2351-2362
24. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7 12 (1997) 1003-1006
25. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., and Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7 68 (1997) 21-30
26. Siervo-Sassi R.R., Marrangoni A.M., Feng X., Naoumova N., Winans M., Edwards R.P., et al. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett. 190 1 (2003) 61-72
27. Deeb D., Jiang H., Gao X., Hafner M.S., Wong H., Divine G., et al. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol. Cancer Ther. 3 7 (2004) 803-812
28. Jung E.M., Lim J.H., Lee T.J., Park J.W., Choi K.S., and Kwon T.K. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 26 11 (2005) 1905-1913
29. Khanbolooki S., Nawrocki S.T., Arumugam T., Andtbacka R., Pino M.S., Kurzrock R., et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 5 9 (2006) 2251-2260
30. Garcea G., Berry D.P., Jones D.J., Singh R., Dennison A.R., Farmer P.B., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomarkers Prev. 14 1 (2005) 120-125
31. Garcea G., Jones D.J., Singh R., Dennison A.R., Farmer P.B., Sharma R.A., et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br. J. Cancer 90 5 (2004) 1011-1015
32. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 10 20 (2004) 6847-6854
33. Sharma R.A., McLelland H.R., Hill K.A., Ireson C.R., Euden S.A., Manson M.M., et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7 7 (2001) 1894-1900
34. Ozols R.F., Bookman M.A., and Young R.C. Intraperitoneal chemotherapy for ovarian cancer. N. Engl. J. Med. 354 15 (2006) 1641-1643 [author reply 1641-3]